Does the media prefer BMY or ZTS?

In the previous week, Zoetis had 13 more articles in the media than Bristol Myers Squibb. MarketBeat recorded 34 mentions for Zoetis and 21 mentions for Bristol Myers Squibb. Bristol Myers Squibb's average media sentiment score of 0.97 beat Zoetis' score of 0.57 indicating that Bristol Myers Squibb is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bristol Myers Squibb 14 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive Zoetis 10 Very Positive mention(s) 1 Positive mention(s) 22 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has better valuation & earnings, RPRX or ZTS?

Zoetis has higher revenue and earnings than Royalty Pharma. Zoetis is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Royalty Pharma $2.38B 13.66 $770.95M $1.47 38.39 Zoetis $9.47B 3.34 $2.67B $6.03 12.52

Is RPRX or ZTS more profitable?

Royalty Pharma has a net margin of 33.88% compared to Zoetis' net margin of 27.80%. Zoetis' return on equity of 66.85% beat Royalty Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Royalty Pharma 33.88% 29.25% 14.71% Zoetis 27.80% 66.85% 18.79%

Does the media refer more to RPRX or ZTS?

In the previous week, Zoetis had 24 more articles in the media than Royalty Pharma. MarketBeat recorded 34 mentions for Zoetis and 10 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 1.35 beat Zoetis' score of 0.57 indicating that Royalty Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Royalty Pharma 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zoetis 10 Very Positive mention(s) 1 Positive mention(s) 22 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to ZTS or JAZZ?

In the previous week, Zoetis had 24 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 34 mentions for Zoetis and 10 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 0.58 beat Zoetis' score of 0.57 indicating that Jazz Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zoetis 10 Very Positive mention(s) 1 Positive mention(s) 22 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Jazz Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, ZTS or CORT?

Zoetis has higher revenue and earnings than Corcept Therapeutics. Zoetis is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zoetis $9.47B 3.34 $2.67B $6.03 12.52 Corcept Therapeutics $761.41M 12.95 $99.65M $0.35 262.51

Does the media refer more to ZTS or CORT?

In the previous week, Zoetis had 20 more articles in the media than Corcept Therapeutics. MarketBeat recorded 34 mentions for Zoetis and 14 mentions for Corcept Therapeutics. Corcept Therapeutics' average media sentiment score of 0.89 beat Zoetis' score of 0.57 indicating that Corcept Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zoetis 10 Very Positive mention(s) 1 Positive mention(s) 22 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Corcept Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ZTS or SUPN?

In the previous week, Zoetis had 30 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 34 mentions for Zoetis and 4 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 0.64 beat Zoetis' score of 0.57 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zoetis 10 Very Positive mention(s) 1 Positive mention(s) 22 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Supernus Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Zoetis (ZTS) Competitors

$75.49 +0.41 (+0.54%)

Closing price 07/10/2026 03:59 PM Eastern

Extended Trading

$75.95 +0.46 (+0.61%)

As of 07/10/2026 07:57 PM Eastern

Compare

ZTS vs. BMY, RPRX, JAZZ, CORT, and SUPN

Should you buy Zoetis stock or one of its competitors? MarketBeat compares Zoetis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Zoetis include Bristol Myers Squibb (BMY), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Corcept Therapeutics (CORT), and Supernus Pharmaceuticals (SUPN). These companies are all part of the "pharmaceuticals" industry.

How does Zoetis compare to Bristol Myers Squibb?

Bristol Myers Squibb (NYSE:BMY) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

Zoetis has a net margin of 27.80% compared to Bristol Myers Squibb's net margin of 15.01%. Zoetis' return on equity of 66.85% beat Bristol Myers Squibb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bristol Myers Squibb	15.01%	64.87%	13.16%
Zoetis	27.80%	66.85%	18.79%

76.4% of Bristol Myers Squibb shares are owned by institutional investors. Comparatively, 92.8% of Zoetis shares are owned by institutional investors. 0.1% of Bristol Myers Squibb shares are owned by company insiders. Comparatively, 0.2% of Zoetis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Bristol Myers Squibb has a beta of 0.23, indicating that its share price is 77% less volatile than the broader market. Comparatively, Zoetis has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market.

Bristol Myers Squibb pays an annual dividend of $2.52 per share and has a dividend yield of 4.4%. Zoetis pays an annual dividend of $2.12 per share and has a dividend yield of 2.8%. Bristol Myers Squibb pays out 70.8% of its earnings in the form of a dividend. Zoetis pays out 35.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol Myers Squibb has increased its dividend for 17 consecutive years and Zoetis has increased its dividend for 14 consecutive years. Bristol Myers Squibb is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, Zoetis had 13 more articles in the media than Bristol Myers Squibb. MarketBeat recorded 34 mentions for Zoetis and 21 mentions for Bristol Myers Squibb. Bristol Myers Squibb's average media sentiment score of 0.97 beat Zoetis' score of 0.57 indicating that Bristol Myers Squibb is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bristol Myers Squibb	14 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive
Zoetis	10 Very Positive mention(s)	1 Positive mention(s)	22 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Bristol Myers Squibb presently has a consensus price target of $61.25, suggesting a potential upside of 6.46%. Zoetis has a consensus price target of $123.46, suggesting a potential upside of 63.56%. Given Zoetis' stronger consensus rating and higher probable upside, analysts clearly believe Zoetis is more favorable than Bristol Myers Squibb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bristol Myers Squibb	1 Sell rating(s)	10 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.37
Zoetis	1 Sell rating(s)	8 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.41

Bristol Myers Squibb has higher revenue and earnings than Zoetis. Zoetis is trading at a lower price-to-earnings ratio than Bristol Myers Squibb, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bristol Myers Squibb	$48.19B	2.44	$7.05B	$3.56	16.16
Zoetis	$9.47B	3.34	$2.67B	$6.03	12.52

Summary

Zoetis beats Bristol Myers Squibb on 12 of the 18 factors compared between the two stocks.

How does Zoetis compare to Royalty Pharma?

Royalty Pharma (NASDAQ:RPRX) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends, profitability and media sentiment.

Royalty Pharma has a net margin of 33.88% compared to Zoetis' net margin of 27.80%. Zoetis' return on equity of 66.85% beat Royalty Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Royalty Pharma	33.88%	29.25%	14.71%
Zoetis	27.80%	66.85%	18.79%

Royalty Pharma presently has a consensus price target of $53.71, suggesting a potential downside of 4.81%. Zoetis has a consensus price target of $123.46, suggesting a potential upside of 63.56%. Given Zoetis' higher probable upside, analysts clearly believe Zoetis is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00
Zoetis	1 Sell rating(s)	8 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.41

54.4% of Royalty Pharma shares are held by institutional investors. Comparatively, 92.8% of Zoetis shares are held by institutional investors. 18.8% of Royalty Pharma shares are held by company insiders. Comparatively, 0.2% of Zoetis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Zoetis has higher revenue and earnings than Royalty Pharma. Zoetis is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Royalty Pharma	$2.38B	13.66	$770.95M	$1.47	38.39
Zoetis	$9.47B	3.34	$2.67B	$6.03	12.52

Royalty Pharma pays an annual dividend of $0.94 per share and has a dividend yield of 1.7%. Zoetis pays an annual dividend of $2.12 per share and has a dividend yield of 2.8%. Royalty Pharma pays out 63.9% of its earnings in the form of a dividend. Zoetis pays out 35.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Royalty Pharma has raised its dividend for 5 consecutive years and Zoetis has raised its dividend for 14 consecutive years. Zoetis is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, Zoetis had 24 more articles in the media than Royalty Pharma. MarketBeat recorded 34 mentions for Zoetis and 10 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 1.35 beat Zoetis' score of 0.57 indicating that Royalty Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Royalty Pharma	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zoetis	10 Very Positive mention(s)	1 Positive mention(s)	22 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Royalty Pharma has a beta of 0.43, indicating that its stock price is 57% less volatile than the broader market. Comparatively, Zoetis has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market.

Summary

Zoetis beats Royalty Pharma on 13 of the 19 factors compared between the two stocks.

How does Zoetis compare to Jazz Pharmaceuticals?

Zoetis (NYSE:ZTS) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk, institutional ownership and media sentiment.

Zoetis has higher revenue and earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zoetis	$9.47B	3.34	$2.67B	$6.03	12.52
Jazz Pharmaceuticals	$4.27B	3.59	-$356.15M	-$0.02	N/A

92.8% of Zoetis shares are owned by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 0.2% of Zoetis shares are owned by insiders. Comparatively, 4.1% of Jazz Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Zoetis had 24 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 34 mentions for Zoetis and 10 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 0.58 beat Zoetis' score of 0.57 indicating that Jazz Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zoetis	10 Very Positive mention(s)	1 Positive mention(s)	22 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Jazz Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Zoetis has a net margin of 27.80% compared to Jazz Pharmaceuticals' net margin of 0.66%. Zoetis' return on equity of 66.85% beat Jazz Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zoetis	27.80%	66.85%	18.79%
Jazz Pharmaceuticals	0.66%	14.56%	5.25%

Zoetis presently has a consensus target price of $123.46, suggesting a potential upside of 63.56%. Jazz Pharmaceuticals has a consensus target price of $252.88, suggesting a potential upside of 3.72%. Given Zoetis' higher probable upside, analysts plainly believe Zoetis is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zoetis	1 Sell rating(s)	8 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.41
Jazz Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.84

Zoetis has a beta of 0.75, meaning that its stock price is 25% less volatile than the broader market. Comparatively, Jazz Pharmaceuticals has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market.

Summary

Zoetis beats Jazz Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Zoetis compare to Corcept Therapeutics?

Zoetis (NYSE:ZTS) and Corcept Therapeutics (NASDAQ:CORT) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends.

Zoetis has higher revenue and earnings than Corcept Therapeutics. Zoetis is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zoetis	$9.47B	3.34	$2.67B	$6.03	12.52
Corcept Therapeutics	$761.41M	12.95	$99.65M	$0.35	262.51

Zoetis has a net margin of 27.80% compared to Corcept Therapeutics' net margin of 6.14%. Zoetis' return on equity of 66.85% beat Corcept Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zoetis	27.80%	66.85%	18.79%
Corcept Therapeutics	6.14%	7.40%	5.76%

92.8% of Zoetis shares are owned by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are owned by institutional investors. 0.2% of Zoetis shares are owned by company insiders. Comparatively, 20.7% of Corcept Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Zoetis has a beta of 0.75, meaning that its share price is 25% less volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market.

In the previous week, Zoetis had 20 more articles in the media than Corcept Therapeutics. MarketBeat recorded 34 mentions for Zoetis and 14 mentions for Corcept Therapeutics. Corcept Therapeutics' average media sentiment score of 0.89 beat Zoetis' score of 0.57 indicating that Corcept Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zoetis	10 Very Positive mention(s)	1 Positive mention(s)	22 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Corcept Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Zoetis currently has a consensus price target of $123.46, suggesting a potential upside of 63.56%. Corcept Therapeutics has a consensus price target of $88.83, suggesting a potential downside of 3.32%. Given Zoetis' higher possible upside, equities analysts clearly believe Zoetis is more favorable than Corcept Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zoetis	1 Sell rating(s)	8 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.41
Corcept Therapeutics	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Zoetis beats Corcept Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Zoetis compare to Supernus Pharmaceuticals?

Zoetis (NYSE:ZTS) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Zoetis currently has a consensus target price of $123.46, suggesting a potential upside of 63.56%. Supernus Pharmaceuticals has a consensus target price of $62.83, suggesting a potential upside of 29.66%. Given Zoetis' higher possible upside, analysts clearly believe Zoetis is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zoetis	1 Sell rating(s)	8 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.41
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Zoetis has higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zoetis	$9.47B	3.34	$2.67B	$6.03	12.52
Supernus Pharmaceuticals	$718.95M	3.91	-$38.55M	-$0.51	N/A

In the previous week, Zoetis had 30 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 34 mentions for Zoetis and 4 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 0.64 beat Zoetis' score of 0.57 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zoetis	10 Very Positive mention(s)	1 Positive mention(s)	22 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Supernus Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zoetis has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market. Comparatively, Supernus Pharmaceuticals has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market.

92.8% of Zoetis shares are owned by institutional investors. 0.2% of Zoetis shares are owned by insiders. Comparatively, 8.5% of Supernus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Zoetis has a net margin of 27.80% compared to Supernus Pharmaceuticals' net margin of -3.74%. Zoetis' return on equity of 66.85% beat Supernus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zoetis	27.80%	66.85%	18.79%
Supernus Pharmaceuticals	-3.74%	13.07%	9.66%

Summary

Zoetis beats Supernus Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

Get Zoetis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZTS vs. The Competition

Export

Metric	Zoetis	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$31.48B	$3.10B	$7.12B	$23.43B
Dividend Yield	2.82%	2.06%	2.68%	4.04%
P/E Ratio	12.52	19.74	27.22	31.27
Price / Sales	3.34	860.65	590.16	20.39
Price / Cash	9.92	57.45	49.34	25.05
Price / Book	9.98	4.29	10.90	4.77
Net Income	$2.67B	$64.32M	$3.57B	$1.07B
7 Day Performance	1.00%	-0.74%	-0.25%	-0.50%
1 Month Performance	-7.39%	6.66%	5.77%	2.09%
1 Year Performance	-51.27%	22.42%	28.14%	16.03%

Zoetis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZTS Zoetis	4.9703 of 5 stars	$75.49 +0.5%	$123.46 +63.6%	-52.5%	$31.48B	$9.47B	12.52	14,500	Trending News
BMY Bristol Myers Squibb	4.5801 of 5 stars	$56.70 -2.5%	$61.31 +8.1%	+18.5%	$115.79B	$48.19B	15.93	32,500	Trending News Analyst Forecast
RPRX Royalty Pharma	4.1263 of 5 stars	$56.92 -1.5%	$53.71 -5.6%	+56.2%	$32.78B	$2.38B	38.72	80	Positive News
JAZZ Jazz Pharmaceuticals	3.6417 of 5 stars	$244.17 +0.3%	$246.06 +0.8%	+116.8%	$15.34B	$4.27B	N/A	2,890	Positive News Analyst Forecast
CORT Corcept Therapeutics	2.6703 of 5 stars	$91.61 +1.6%	$88.83 -3.0%	+27.6%	$9.83B	$761.41M	261.75	300	News Coverage Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ZTS) was last updated on 7/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zoetis (ZTS) Competitors

ZTS vs. BMY, RPRX, JAZZ, CORT, and SUPN

How does Zoetis compare to Bristol Myers Squibb?

Summary

How does Zoetis compare to Royalty Pharma?

Summary

How does Zoetis compare to Jazz Pharmaceuticals?

Summary

How does Zoetis compare to Corcept Therapeutics?

Summary

How does Zoetis compare to Supernus Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZTS vs. The Competition

Zoetis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zoetis (ZTS) Competitors

ZTS vs. BMY, RPRX, JAZZ, CORT, and SUPN

How does Zoetis compare to Bristol Myers Squibb?

Is BMY or ZTS more profitable?

Do insiders & institutionals have more ownership in BMY or ZTS?

Which has more volatility and risk, BMY or ZTS?

Is BMY or ZTS a better dividend stock?

Does the media prefer BMY or ZTS?

Do analysts rate BMY or ZTS?

Which has higher earnings and valuation, BMY or ZTS?

Summary

How does Zoetis compare to Royalty Pharma?

Is RPRX or ZTS more profitable?

Do analysts prefer RPRX or ZTS?

Do institutionals and insiders believe in RPRX or ZTS?

Which has better valuation & earnings, RPRX or ZTS?

Is RPRX or ZTS a better dividend stock?

Does the media refer more to RPRX or ZTS?

Which has more volatility & risk, RPRX or ZTS?

Summary

How does Zoetis compare to Jazz Pharmaceuticals?

Which has preferable valuation & earnings, ZTS or JAZZ?

Do institutionals & insiders hold more shares of ZTS or JAZZ?

Does the media refer more to ZTS or JAZZ?

Is ZTS or JAZZ more profitable?

Do analysts prefer ZTS or JAZZ?

Which has more risk & volatility, ZTS or JAZZ?

Summary

How does Zoetis compare to Corcept Therapeutics?

Which has stronger earnings and valuation, ZTS or CORT?

Is ZTS or CORT more profitable?

Do institutionals and insiders hold more shares of ZTS or CORT?

Which has more risk and volatility, ZTS or CORT?

Does the media refer more to ZTS or CORT?

Do analysts prefer ZTS or CORT?

Summary

How does Zoetis compare to Supernus Pharmaceuticals?

Do analysts prefer ZTS or SUPN?

Which has preferable earnings and valuation, ZTS or SUPN?

Does the media favor ZTS or SUPN?

Which has more volatility and risk, ZTS or SUPN?

Do institutionals & insiders have more ownership in ZTS or SUPN?

Is ZTS or SUPN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZTS vs. The Competition

Zoetis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools